| Project/Area Number |
20591957
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
YAMADA Yoshihiko Nara Medical University, 医学部, 講師 (80275346)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOBAYASHI Hiroshi 奈良県立医科大学, 医学部, 教授 (40178330)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 卵巣がん / 分子標的抗腫瘍薬 / 浸潤 / アノイキス / マイクロアレイ / 卵巣癌 / 抗がん剤感受性 / 細胞浸潤 / 細胞周期 |
|---|
| Research Abstract |
We were going to search for the antitumor material which resembled thalidomide by analyzing a function of HNF-1beta which specifically developed in the clear cell adenocarcinoma which was intractable ovarian cancer high. HNF-1beta was proved to be involved in the invasion ability of the tumor, antiapoptosis and anticancer drug resistance. Furthermore, we analyzed a function of HNF-1beta about the cell cycle. As a result, because HNF-1beta made a phosphorylation of chk1 persist, we caused the activation of the persistent checkpoint of the cancer cell, and it became clear that it was with one of the factors that were the carcinostatic of the ovary clear cell adenocarcinoma-resistant in its turn. It is said that most of cancer cells depend on the G2/M checkpoint for DNA repair, and it is thought that it may be with the target of the new drug for the ovarian clear cell adenocarcinoma in chk1 involved in the G2/M checkpoint.
|
